全文获取类型
收费全文 | 37822篇 |
免费 | 2464篇 |
国内免费 | 762篇 |
专业分类
耳鼻咽喉 | 158篇 |
儿科学 | 822篇 |
妇产科学 | 430篇 |
基础医学 | 5102篇 |
口腔科学 | 382篇 |
临床医学 | 3684篇 |
内科学 | 7402篇 |
皮肤病学 | 438篇 |
神经病学 | 1100篇 |
特种医学 | 572篇 |
外国民族医学 | 2篇 |
外科学 | 2178篇 |
综合类 | 2733篇 |
现状与发展 | 3篇 |
一般理论 | 48篇 |
预防医学 | 10556篇 |
眼科学 | 398篇 |
药学 | 2475篇 |
29篇 | |
中国医学 | 588篇 |
肿瘤学 | 1948篇 |
出版年
2024年 | 104篇 |
2023年 | 2690篇 |
2022年 | 5786篇 |
2021年 | 7511篇 |
2020年 | 5247篇 |
2019年 | 872篇 |
2018年 | 904篇 |
2017年 | 763篇 |
2016年 | 810篇 |
2015年 | 926篇 |
2014年 | 1174篇 |
2013年 | 1568篇 |
2012年 | 1158篇 |
2011年 | 1361篇 |
2010年 | 1139篇 |
2009年 | 1088篇 |
2008年 | 772篇 |
2007年 | 958篇 |
2006年 | 854篇 |
2005年 | 719篇 |
2004年 | 701篇 |
2003年 | 626篇 |
2002年 | 463篇 |
2001年 | 416篇 |
2000年 | 350篇 |
1999年 | 317篇 |
1998年 | 236篇 |
1997年 | 218篇 |
1996年 | 184篇 |
1995年 | 122篇 |
1994年 | 97篇 |
1993年 | 103篇 |
1992年 | 74篇 |
1991年 | 82篇 |
1990年 | 71篇 |
1989年 | 69篇 |
1988年 | 53篇 |
1987年 | 42篇 |
1986年 | 39篇 |
1985年 | 87篇 |
1984年 | 64篇 |
1983年 | 39篇 |
1982年 | 39篇 |
1981年 | 34篇 |
1980年 | 23篇 |
1979年 | 19篇 |
1978年 | 13篇 |
1977年 | 13篇 |
1975年 | 10篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
核酸疫苗自诞生以来在肿瘤、感染性疾病和自身免疫性疾病等方面显示出其独特的优越性。目前,研究如何增强核酸疫苗的免疫原性是一大热点,在众多方法中,电穿孔通过增加细胞对DNA的摄取,使表达的目的抗原增多,从而明显地增强了核酸疫苗诱导的免疫反应。就电穿孔技术在核酸疫苗研究领域的应用作一综述。 相似文献
102.
Payeras A Martinez P Milà J Riera M Pareja A Casal J Matamoros N 《Clinical and experimental immunology》2002,130(2):271-278
The aim of the study was to determine possible factors related to the risk of developing recurrent bacterial respiratory tract infections in HIV-1-infected patients, regardless of the degree of immune cellular impairment. Thirty-three HIV-1 seropositive patients with previous repetitive bacterial respiratory tract infections (case group), 33 HIV-1 seropositive controls (matched by CD4-cell counts) without these antecedents and 27 healthy controls were studied before and after administration of pneumococcal and Haemophilus influenzae type b vaccines. Clinical or toxicological variables, cutaneous tests, complement factors, beta2-microglobulin, serum IgM, IgA, IgG and subclasses, specific antibodies (IgG, IgG2, IgA) against pneumococcal vaccine and polyribosylribitol phosphate (PRP), their avidity, opsonophagocytosis and IgG(2)m and Fc(gamma)RIIa allotypes were determined. A history of drug abuse (P = 0.001), less likelihood of receiving high activity antiretroviral treatment high activity antiretroviral treatment (HAART) (P = 0.01), higher levels of HIV-1 viral load (P < 0.05), serum IgG (P < 0.01) and beta2-microglobulin (P < 0.01) were observed in the case group. Also, a lower increase in specific antibodies to pneumococcal vaccine and PRP was demonstrated in the cases in comparison with the two control groups. No differences were observed in the avidity of antibodies, opsonophagocytic capacity or IgG(2)m and Fc(gamma)RIIa allotypes between the three groups. These data indicate that vaccination strategies against encapsulated bacteria can be unsuccessful in the HIV-1-infected patients presenting repetitive bacterial respiratory tract infections if behavioural aspects or measures to improve adherence to HAART therapies are not considered. 相似文献
103.
Bonvicini F Gallinella G Cricca M Ambretti S Delbarba S Musiani M Zerbini M 《Journal of medical virology》2004,74(2):272-276
B19 virus can be transmitted by contaminated blood or blood products. Recent observations, in healthy volunteers, suggest that active B19 infection can follow the administration of plasma pools with a concentration > or =10(7) genome equivalents/ml (geq/ml) of B19 DNA. However, patients receiving batches with levels of virus DNA lower than 10(4) geq/ml do not show any evidence of transmission of the virus. The aim of the study was to show, by in vitro assays, a threshold of viral load in B19 contaminated plasma pools over which the infection can be transmitted. Twenty plasma pools, each containing 960 single donations, were tested to correlate the viral load and the level of antibodies anti-B19 with the in vitro infectivity and expression of B19 virus. All the plasma pools, titrated for B19 viral load by competitive PCR, were inoculated into KU812Ep6 erythroid human cell line. Five of the nine contaminated plasma pools, with a B19 DNA concentration > or =3.60 x 10(6) geq/ml, were able to infect KU812Ep6 cells. In vitro infectivity was shown in KU812Ep6 cells at 24 h post-infection by in situ hybridisation and amplification assays for viral DNA and RNAs. Plasma pools with a viral load in the range of 6.00 x 10(3)-8.96 x 10(4) geq/ml did not show infectivity when inoculated into KU812Ep6 cells. Medium-high titres of IgG antibodies anti-B19 were detectable in all the plasma pools and the neutralising activity associated with specific IgG anti-B19 may explain the lack of infectivity of plasma pools contaminated with a low viral load. In conclusion, in situ hybridisation and amplification assays for viral DNA and RNAs in KU812Ep6 cells inoculated with plasma pools can be valid assays to test for the presence of infectious virus in the production of B19-safe material. 相似文献
104.
Wolfgang Müller-Felber Klaus Küllmer Petra Fischer Carl-Detlev Reimers Stefan Wagner Ullrich Harland Martin Schmidt-Achert Dieter Pongratz 《Virchows Archiv : an international journal of pathology》1993,422(4):277-283
Leu-19 antigen, which seems to be identical with neural cell adhesion molecule (N-CAM), plays a major role in the innervation of muscle cells, and in adult muscle appears after denervation and during regeneration of muscle fibres, where it acts as part of a signalling system increasing the probability of re-innervation. This combined enzyme-histochemical and immunohistochemical study examined whether this signalling process was regulated in a uniform or differential pattern for type 1 and type 2 muscle fibres. The subscapular nerve of 18 rabbits was transsected with subsequent complete denervation of the supraspinatus muscle. Leu19 and N-CAM immunohistochemistry was performed 2 to 64 days after surgery. Whereas in normal muscle there are virtually no Leu-19/N-CAM positive muscle fibres; from day 2 after denervation an increasing proportion of fibres expressed Leu-19/N-CAM, prior to any neurogenic atrophy. In the early stage of denervation Leul9/N-CAM expression was confined to type 1 fibres. After 11 days nearly all fibres were Leul9/N-CAM positive irrespective of their fibre type. Sixty-four days after denervation type 1 fibres became Leu19/N-CAM negative, while atrophic type 2 fibres showed intensive staining. Thus, expression of Leu-19 antigenity is differently regulated in both fibre types. 相似文献
105.
乙肝疫苗免疫失败儿童病毒S基因"a"决定簇变异研究 总被引:4,自引:0,他引:4
王永忠 《中国优生与遗传杂志》2003,11(4):29-30
目的 探讨江苏常州地区乙型肝炎疫苗免疫失败儿童病毒S基因“a”决定簇的变异情况。方法 对15例乙肝疫苗接种后血清表面抗原(HBsAg)阳性的儿童,采用聚合酶链反应方法(PCR)扩增其血清中HBV DNA S基因区。并对PCR产物直接标记测序。结果 15例HBsAg阳性儿童有14例血清HBV DNA阳性,其中有4例出现了S基因“a”决定簇的变异,变异率为28.6%,第126位的异亮氨酸(Ile)被苏氨酸(Thr)替代1例,第134位苯丙氨酸(Phe)被异亮氨酸替代1例。第145位甘氨酸(Gly)被丙氨酸(Pha)替代2例。结论乙型肝炎疫苗免疫失败儿童中存在s基因“a”抗原决定簇变异,江苏常州地区存在HBVS基因“a”决定簇变异的新类型。 相似文献
106.
表达前列腺特异性膜抗原的DNA疫苗对肿瘤细胞的抑制作用 总被引:3,自引:0,他引:3
目的构建表达前列腺特异性膜抗原(PSMA)的DNA疫苗,观察其在体外对肿瘤细胞的免疫攻击和在体内对肿瘤细胞攻击的免疫保护作用。方法通过稳定转染构建表达PSMA的小鼠黑色素瘤细胞系B16-PSMA,将DNA疫苗pCDNA3.1-PSMA通过肌肉注射导入C57BL/6小鼠体内,分离小鼠脾细胞,检测细胞毒性T淋巴细胞(cytotoxic T lymphocytes,CTL)反应。以B16-PSMA细胞攻击免骺小鼠,观察免疫动物的无瘤生存期和肿瘤体积增长情况,评价DNA疫苗的抗肿瘤作用。结果DNA疫苗可诱导小鼠脾淋巴细胞CTL活性,经过免疫后的小鼠成瘤率降低,无瘤生存期延长,肿瘤生长缓慢,肿瘤组织内有较多淋巴细胞浸润,表明产生较强的抗肿瘤反应。结论表达PSMA的DNA疫苗能够诱导小鼠产生特异性免疫反应,对表达PSMA的肿瘤细胞的攻击产生免疫保护作用,为前列腺癌的预防和免疫治疗提供了新的思路。 相似文献
107.
van Noesel Carel J. M.; Lankester Arjan C.; van Schijndel Gijs M. W.; van Lier Rene A. W. 《International immunology》1993,5(7):699-705
The complement receptor 2 (CR2 or CD21) can be found in non-covalentassociation with the Blymphocyte specific CD19 complex at thesurface of mature human B cells. Upon ligation of the B cellantigen receptor complex (BCR), members of the CR2-CD19 complexmay associate with membrane immunoglobulin (mlg). Moreover,CD19 and CD21 ligands, either murine mAb, C3d fragments or Epstein—Barrvirus, are known to have profound effects on B cell activation.We here show that CD19 is tightly linked to the non-receptorsrc kinase Lyn and that the CD19 glycoprotein itself servesas a substrate for a yet undefined serine/threonine kinase presentwithin the complex. In the process of antigen recognition, mlgand the CR2-CD19 complex may bind different sites of a complement-opsonizedantigenic particle. We hypothesize that in this process, approximationto the BCR allows CD19-associated Lyn kinase to phosphorylatepotential substrates within the antigen—receptor complex,thereby effecting its coupling to the intracellular compartment. 相似文献
108.
Hess AD Thoburn C Chen W Miura Y Van der Wall E 《Clinical immunology (Orlando, Fla.)》2001,101(1):67-76
The N-terminal flanking region of the invariant chain peptide termed CLIP appears to have superagonistic properties interacting with the T cell receptor and the MHC class II molecule at or near the binding site for the bacterial superantigen Staphylococcal enterotoxin B (SEB). The present studies explored the hypothesis that the N-terminal segment of CLIP can augment the immunogenicity of cryptic "self" tumor-associated antigens. A chimeric construct of an MHC class II binding peptide from the c-erb oncogene (Her-2/neu) containing the N-terminal flanking region of CLIP elicited potent antitumor activity against a Her-2/neu-positive tumor in a rat model system. Comparatively, the unmodified parent peptide was ineffective. The induction of effective antitumor immunity, however, required presentation of the chimeric peptide construct on irradiated tumor cells or the peptide construct in concert with a Her-2/neu MHC class I-restricted peptide from Her-2/neu. As revealed by adoptive transfer studies, effective protective antitumor immunity in this setting required the CD4 T helper subset. Additionally, in vitro analysis revealed that immunization with the parent peptide resulted in a weak immune response to the unmodified peptide consisting of both type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-10) cytokine-producing cells analyzed by RT-PCR (qualitative and quantitative) and by limiting dilution assay. Comparatively, immunization with the chimeric construct elicited a potent immune response to the parent peptide with predominantly type 1 cytokine-producing cells. Taken together, the results suggest that immunization with the chimeric Her-2/neu peptide induced protective antitumor immunity. Associated with this immunization strategy was the enhancement of a type 1 cytokine response. 相似文献
109.
C. B. Laval A. L. S. S. de rade F. C. Pimenta J. G. de Andrade R. M. de Oliveira S. A. Silva E. C. de Lima J. L. Di Fabio S. T. Casagrande M. C. C. Brandileone 《Clinical microbiology and infection》2006,12(1):50-55
Nasopharyngeal carriage of Streptococcus pneumoniae is a key factor in the development of invasive disease and the spread of resistant strains within the community. A single nasopharyngeal swab was obtained from 648 unvaccinated children aged <5 years, either healthy or with acute respiratory tract infection or meningitis, during the winters of 2000 and 2001. The overall pneumococcal carriage rate was 35.8% (95% CI 32.1-39.6). The pneumococcal serotypes found most frequently in the nasopharynx were 14, 6B, 6A, 19F, 10A, 23F and 18C, which included five of the seven serotypes in the currently licensed seven-valent conjugate vaccine (PCV7); serotypes 4 and 9V were less common. Serotypes 1 and 5 were isolated rarely from the nasopharynx. A comparison of 222 nasopharyngeal isolates with 125 invasive isolates, matched for age and time to the carrier isolates, showed a similar prevalence of penicillin non-susceptible pneumococci (PNSp) (19.8% and 19.2%, respectively). PNSp serotypes were similar (6B, 14, 19F, 19 A, 23B and 23F) for carriage and invasive disease isolates. The coverage of PCV7 for carriage isolates (52.2%) and invasive isolates (62.4%) did not differ significantly (p 0.06); similarly, there was no significant difference in PCV7 coverage for carriage isolates (34.5%) and invasive isolates (28.2%) of PNSp. These data suggest that PCV7 has the potential to reduce pneumococcal carriage and the number of carriers of PNSp belonging to vaccine serotypes. 相似文献
110.
Deniz Eyice Karabacak Semra Demir Osman Ozan Yeğit Ali Can Kadriye Terzioğlu Derya Ünal Müge Olgaç Raif Coşkun Bahauddin Çolakoğlu Suna Büyüköztürk Aslı Gelincik 《Allergy》2021,76(8):2535-2543